Balaxi Pharmaceuticals Launches Commercial Production in Hyderabad; Reports Q1 Results
Balaxi Pharmaceuticals Limited has reported its unaudited financial results for the quarter ending June 30, 2026, alongside detailing significant progress at its new pharmaceutical formulation plant. The company confirmed that it has commenced commercial manufacturing operations and expanded its approved product portfolio.The Board of Directors took note of the operational status of the company’s first pharmaceutical formulation facility in Jadcherla, Hyderabad. Management reported that the company has successfully initiated commercial production at the site, beginning with two initial products: Paracetamol Tablets 500mg and Piroxicam Capsules 20mg.
The Board noted that the company has secured manufacturing product permissions for an additional 29 products. This brings the total approved commercial product portfolio to 31 items. Raw materials and key input materials are arriving at the facility, and commercial production is planned to be initiated progressively based on market requirements.
Manufacturing Milestones and Compliance
The Board was apprised of the outcome of the WHO-GMP audit conducted in July 2026 by a joint inspection involving CDSCO and the State FDA. The company has submitted its CAPA response (Corrective Action Preventive Action) to regulatory authorities for review and is currently on track to obtain WHO-GMP certification, which is noted as crucial for strengthening future growth opportunities.Quarterly Financial Performance
Balaxi Pharmaceuticals provided both standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.The company’s operational segment is categorized as "Specialized Wholesale." The Q1 performance data highlights the following key metrics (in Rs in lakhs):
Financial Highlights: Standalone Results (Quarter Ended 30.06.2026)
| Particulars | Current Quarter (30.06.2026) | Previous Quarter (31.03.2026) | Previous Year (30.06.2025) | Last Fiscal Year (31.03.2026) |
|---|---|---|---|---|
| Revenue from operations | 1,558.37 | 2,023.96 | 1,670.82 | 8,085.11 |
| Total Income | 1,649.99 | 2,360.65 | 1,717.04 | 9,051.83 |
| Cost of Goods Sold | 1,336.27 | 1,741.63 | 1,117.59 | 6,911.42 |
| Profit/(loss) before tax | (111.65) | 41.35 | 25.83 | 703.28 |
| Net Profit/(Loss) for the period | (125.32) | 15.80 | 19.49 | 514.68 |
Financial Highlights: Consolidated Results (Quarter Ended 30.06.2026)
The consolidated results encompass operations across various subsidiaries, including those based in the Dominican Republic, Honduras, El Salvador, Angola, Nicaragua, and Ecuador.
| Particulars | Current Quarter (30.06.2026) | Previous Quarter (31.03.2026) | Previous Year (30.06.2025) | Last Fiscal Year (31.03.2026) |
|---|---|---|---|---|
| Revenue from operations | 8,068.18 | 7,071.37 | 7,074.21 | 27,017.35 |
| Total Income | 7,968.97 | 7,363.10 | 6,896.55 | 27,299.47 |
| Cost of Goods Sold | 4,317.37 | 4,053.08 | 3,955.99 | 15,087.53 |
| Profit/(loss) before tax | 208.92 | 140.26 | 90.34 | 529.26 |
| Net Profit/(Loss) for the period | 129.74 | 61.28 | 29.01 | 141.69 |
The company reported earnings per share (EPS) as follows:
- Standalone EPS: Basic was reported as less than 0.23, while Diluted EPS stood at (0.23).
- Consolidated EPS: The basic EPS for the quarter was recorded at 0.24, with a diluted EPS of 0.24.
BALAXI Stock Price Movement
Shares of BALAXI PHARMACEUTICALS LIMITED are edging higher as of 2:50 PM, climbing 0.50% to ₹24.15 after gaining ₹0.12 in trading activity. The stock currently maintains momentum within the day's range, having seen a high of ₹25.4 and a low of ₹23.8.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: